We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Corbus Stock Down as Lenabasum Fails to Meet Primary Endpoint
Read MoreHide Full Article
Shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP - Free Report) fell 35.9% after it announced disappointing top-line results from its 28-week phase IIb study of lenabasum in patients with cystic fibrosis (CF). However, shares of the company have slumped 77.8% year to date compared with the industry’s decline of 7.9%.
CF-002 was a multinational phase IIb study evaluating the efficacy and safety of lenabasum in CF. The study enrolled patients in the United States, Canada and Europe at high risk ofrecurrent pulmonary exacerbations (PEx). Patients were randomized to receive either 5 mg or 20 mg of lenabasum, or placebo, twice daily. While lenabasum had a favorable safety profile and was well-tolerated, the 28-week study did not meet its primary endpoint of a statistically significant reduction in the rate of new PEx per subject per 28 weeks.
Lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist that resolves chronic inflammation and limits fibrosis in animal and human models. The drugis currently being evaluated in dermatomyositis and systemic lupus erythematosus. Corbus is also developing a pipeline of other drug candidates from its endocannabinoid system platform.
There are several other companies,whichhave products either developed or in development for the treatment of CF.Vertex Pharmaceuticals Incorporated (VRTX - Free Report) has Kalydeco in its portfolio for CF. Another company, AzurRx , is evaluating MS1819 in combination with porcine enzyme replacement therapy (PERT) in twoclinical programs examining MS1819 in a phase IIb CF monotherapy and phase II CF combination approach.
Emergent’s earnings estimates have increased from $4.03 to $6.61 for 2020 and from $5.07 to $8.42 for 2021 over the past 90 days. Shares of the company have increased 106.3% year to date.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity. A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Corbus Stock Down as Lenabasum Fails to Meet Primary Endpoint
Shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP - Free Report) fell 35.9% after it announced disappointing top-line results from its 28-week phase IIb study of lenabasum in patients with cystic fibrosis (CF). However, shares of the company have slumped 77.8% year to date compared with the industry’s decline of 7.9%.
CF-002 was a multinational phase IIb study evaluating the efficacy and safety of lenabasum in CF. The study enrolled patients in the United States, Canada and Europe at high risk ofrecurrent pulmonary exacerbations (PEx). Patients were randomized to receive either 5 mg or 20 mg of lenabasum, or placebo, twice daily. While lenabasum had a favorable safety profile and was well-tolerated, the 28-week study did not meet its primary endpoint of a statistically significant reduction in the rate of new PEx per subject per 28 weeks.
Lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist that resolves chronic inflammation and limits fibrosis in animal and human models. The drugis currently being evaluated in dermatomyositis and systemic lupus erythematosus. Corbus is also developing a pipeline of other drug candidates from its endocannabinoid system platform.
There are several other companies,whichhave products either developed or in development for the treatment of CF. Vertex Pharmaceuticals Incorporated (VRTX - Free Report) has Kalydeco in its portfolio for CF. Another company, AzurRx , is evaluating MS1819 in combination with porcine enzyme replacement therapy (PERT) in twoclinical programs examining MS1819 in a phase IIb CF monotherapy and phase II CF combination approach.
Corbus Pharmaceuticals Holdings, Inc. Price
Corbus Pharmaceuticals Holdings, Inc. price | Corbus Pharmaceuticals Holdings, Inc. Quote
Zacks Rank & A Stock to Consider
Corbus currently carries a Zacks Rank #4 (Sell).
A better-ranked stock in the healthcare sector includes Emergent Biosolutions Inc. (EBS - Free Report) , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Emergent’s earnings estimates have increased from $4.03 to $6.61 for 2020 and from $5.07 to $8.42 for 2021 over the past 90 days. Shares of the company have increased 106.3% year to date.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity. A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>